Metallothioneins and platinum(II) anti-tumor compounds

Current Medicinal Chemistry

Volumn 16, Issue 5, 2009, Pages 522-537

  Knipp, Markus ^a  

^a MAX PLANCK INSTITUTE FOR CHEMICAL ENERGY CONVERSION   (Germany)

Author keywords

Anti tumor drugs; Cancer; Cisplatin; Metallothionein; Platinum treatment; Sulfur platinum interaction; Transplatin

Indexed keywords

(1 IMINO 1 METHOXYETHANE)AMMINEDICHLOROPLATINUM; (2 METHYLBUTYLAMINE)AMMINEDICHLOROPLATINUM; (2 METHYLPYRIDINE)AMMINEDICHLORIDOPLATINUM; (BIS 1 IMINO 1 METHOXYETHANE)DICHLOROPLATINUM; (ISOPROPYLAMINE)(2 METHYLBUTYLAMINE)DICHLOROPLATINUM; 2 AMINO 3 PHOSPHONOPROPIONIC ACID; AMD 443; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; AP 1; BIS(1 IMINO 1 METHOXYETHANE)DICHLOROPLATINUM; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; GLUTATHIONE; MELPHALAN; METALLOTHIONEIN; OXALIPLATIN; PLATINUM COMPLEX; TRANSPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLADDER CANCER; CANCER RESISTANCE; COLORECTAL CANCER; CROSS RESISTANCE; DNA DRUG COMPLEX; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEARING DISORDER; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CARCINOMA; PROSTATE CANCER; REVIEW; STOMACH CANCER; TESTIS CANCER; TINNITUS; UTERINE CERVIX CANCER; WEAKNESS; CHEMICAL STRUCTURE; CHEMISTRY; MOLECULAR GENETICS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; METALLOTHIONEIN; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 63149164307     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787458452     Document Type: Review

References (175)

1. Kägi, J. H. R.; Vallee, B. L. Metallothionein: A cadmium- and zinc-containing protein from equine renal cortex. J. Biol. Chem., 1960, 235, 3460-3465.
2. Romero-Isart, N.; Vašák, M. Advances in the structure and chemistry of metallothioneins. J. Inorg. Biochem., 2002, 88, 388-396.
3. Kraker, A.; Schmidt, J.; Krezoski, S.; Petering, D. H. Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells. Biochem. Biophys. Res. Commun., 1985, 130, 786-792.
4. Miles, A. T.; Hawksworth, G. M.; Beattie, J. H.; Rodilla, V. Induction, regulation, degradation, and biological significance of mammalian metallothionein. Crit. Rev. Biochem. Mol. Biol., 2000, 35, 35-70.
5. 3β domains from Homarus americanus metallothionein-1: Hydrogen bonding and solvent accessibility of sulfur atoms. J. Biol. Inorg. Chem., 2002, 7, 713-724.
6. Vallee, B. L.; Auld, D. S. Zinc metallochemistry in biochemistry. EXS, 1995, 73, 259-277.
7. Palmiter, R. D. The elusive function of metallothioneins. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 8428-8430;
8. Maret, W. The function of zinc metallothionein: A link between cellular zinc and redox state. J. Nutr., 2000, 130 (Suppl.), 1455S-1458S;
9. Hidalgo, J.; Aschner, M.; Zatta, P.; Vašák, M. Roles of the metallothionein family of proteins in the central nervous system. Brain Res. Bull., 2001, 55, 133-145.
10. Lichtlen, P.; Schaffner, W. Putting its fingers on stressful situations: The heavy metal-regulatory transcription factor MTF-1. BioEssays, 2001, 23, 1010-1017.
11. Garrett, S. H.; Sens, M. A.; Shukla, D.; Nestor, S.; Somji, S.; Todd, J. H.; Sens, D. A. Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate, 1999, 41, 196-202.
12. Romero-Isart, N.; Jensen, L. T.; Zerbe, O.; Winge, D. R.; Vašák, M. Engineering of metallothionein-3 neuroinhibitory activity into the inactive isoform metallothionein-1. J. Biol. Chem., 2002, 277, 37023-37028.
13. Vašák, M.; Romero-Isart, N. Metallothioneins. In Encyclopedia of Inorganic Chemistry; 2 ed.; King, R. B. Ed.; John Wiley & Sons, Ltd: Chichester (UK), 2005; pp 3208-3221.
14. Vašák, M.; Hasler, D. W. Metallothioneins: New functional and structural insights. Curr. Opin. Chem. Biol., 2000, 4, 177-183.
15. Kägi, J. H. R. Evolution, structure and chemical activity of class I metallothioneins: An overview. In Metallothionein III - Biological Roles and Medical Implications; Suzuki, K. T., Imura, N., Kimura, M. Eds.; Birkhäuser Verlag: Basel (Switzerland), 1993; pp 29-56.
16. Nettesheim, D. G.; Engeseth, H. R.; Otvos, J. D. Products of metal exchange reactions of metallothionein. Biochemistry, 1985, 24, 6744-6751;
17. Vašák, M.; Nicholson, J. K.; Hawkes, G. E.; Sadler, P. J. Biochemistry, 1985, 24, 740;
18. 6-metallothionein-2a. Biochem. J., 1988, 253, 611-614.
19. Bertini, I.; Luchinat, C.; Messori, L.; Vašák, M. Proton NMR studies of the cobalt(II)-metallothionein system. J. Am. Chem. Soc., 1989, 111, 7296-7300.
20. Vašák, M.; Kägi, J. H. R.; Holmquist, B.; Vallee, B. L. Spectral studies of cobalt(II)- and nickel(II)-metallothionein. Biochemistry, 1981, 20, 6659-6664.
21. 113Cd NMR studies of reconstituted seven-cadmium metallothionein: Evidence for structural flexibility. 1985, 24, 740-747.
22. Henkel, G.; Krebs, B. Metallothioneins: Zinc, cadmium, mercury, and copper thiolates and selenolates mimicking protein active site features - Structural aspects and biological implications. Chem. Rev., 2004, 104, 801-824.
23. Sun, H.; Li, H.; Harvey, I.; Sadler, P. J. Interactions of bismuth complexes with metallothionein(II). J. Biol. Chem., 1999, 274, 29094-29101.
24. Good, M.; Vašák, M. Iron(II)-substituted metallothionein: Evidence for the existence of iron-thiolate clusters. Biochemistry, 1986, 25, 8353-8356.
25. Winge, D. R. Copper coordination in metallothionein. Methods Enzymol., 1991, 205, 458-469.
26. 5-metallothionein. J. Inorg. Biochem., 2001, 83, 1-6.
27. Waalkes, M. P.; Liu, J.; Goyer, R. A.; Diwan, B. A. Metallothionein-I/II double knockout mice are hypersensitive to leadinduced kidney carcinogenesis: Role of inclusion body formation. Cancer Res., 2004, 64, 7766-7772.
28. 7]-metallothionein-2 from rat liver in aqueous solution determined by nuclear magnetic resonance spectroscopy. J. Mol. Biol., 1988, 203, 251-268.
29. Robbins, A. H.; McRee, D. E.; Williamson, M.; Collett, S. A.; Xuong, N. H.; Furey, W. F.; Wang, B. C.; Stout, C. D. Refined crystal structure of Cd, Zn metallothionein at 2.0 Å resolution. J. Mol. Biol., 1991, 221, 1269-1293.
30. Faller, P.; Hasler, D. W.; Zerbe, O.; Klauser, S.; Winge, D. R.; Vašák, M. Evidence for a dynamic structure of human neuronal growth inhibitory factor and for major rearrangements of its metalthiolate clusters. Biochemistry, 1999, 38, 10158-10167;
31. Öz, G.; Zangger, K.; Armitage, I. M. Three-dimensional structure and dynamics of a brain specific growth inhibitory factor: Metallothionein-3. Biochemistry, 2001, 40, 11433-11441;
32. Wang, H.; Zhang, Q.; Cai, B.; Li, H.; Sze, K.-H.; Huang, Z.-X.; Wu, H.-M.; Sun, H. Solution structure and dynamics of human metallothionein-3 (MT-3). FEBS Lett., 2006, 580, 795-800.
33. Faller, P.; Vašák, M. Distinct metal-thiolate clusters in the N-terminal domain of neuronal growth inhibitory factor. Biochemistry, 1997, 36, 13341-13348;
34. 4-thiolate cluster of human metallothionein-3 is located in the N-terminal domain. J. Biol. Inorg. Chem., 2002, 7, 611-616;
35. 4-metallothionein-3. Biochemistry, 2003, 42, 9822-9828;
36. Bogumil, R.; Faller, P.; Pountney, D. L.; Vašák, M. Evidence for Cu(I) clusters and Zn(II) clusters in neuronal growth-inhibitory factor isolated from bovine brain. Eur. J. Biochem., 1996, 238, 698-705;
37. Bogumil, R.; Faller, P.; Binz, P. A.; Vašák, M.; Charnock, J. M.; Garner, C. D. Structural characterization of Cu(I) and Zn(II) sites in neuronal-growth-inhibitory factor by extended X-ray absorption fine structure (EXAFS). Eur. J. Biochem., 1998, 255, 172-177.
38. Meloni, G.; Zovo, K.; Kazantseva, J.; Palumaa, P.; Vašák, M. Organization and assembly of metal-thiolate clusters in epithelium-specific metallothionein-4. J. Biol. Chem., 2007, 281, 14588-14595.
39. II compounds retain their N-donor ligands. J. Med. Chem., 2007, 50, 4075-4086.
40. Guex, N.; Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis, 1997, 18, 2714-2723.
41. Auld, D. S. Zinc coordination sphere in biochemical zinc sites. BioMetals, 2001, 14, 271-313;
42. Maret, W. Zinc and sulfur: A critical biological partnership. Biochemistry, 2004, 43, 3301-3309.
43. Shaw III, C. F.; Savas, M. M.; Petering, D. H. Ligand substitution and sulfhydryl reactivity of metallothionein. Methods Enzymol., 1991, 205, 401-414.
44. Smyth, D. G.; Nagamatsu, A.; Fraton, J. S. Some reactions of N-ethylmaleimide. J. Am. Chem. Soc., 1960, 82 4600-4604.
45. Meloni, G.; Knipp, M.; Vašák, M. Detection of neuronal growth inhibitory factor (metallothionein-3) in polyacrylamide gels and by Western blot analysis. J. Biochem. Biophys. Methods, 2005, 64, 76-81.
46. Li, T.-Y.; Minkel, D. T.; Shaw III, C. F.; Petering, D. H. On the reactivity of metallothioneins with 5,5′-dithiobis-(2-nitrobenzoic acid). Biochem. J., 1981, 193, 441-446.
47. Bernhard, W. R. Differential modification of metallothionein with iodoacetamide. Methods Enzymol., 1991, 205, 426-433.
48. Yu, X.; Wu, Z.; Fenselau, C. Covalent sequestration of melphalan by metallothionein and selective alkylation of cysteines. Biochemistry, 1995, 34, 3377-3385;
49. Zaia, J.; Jiang, L. C.; Han, M. S.; Tabb, J. R.; Wu, Z. C.; Fabris, D.; Fenselau, C. A binding site for chlorambucil on metallothionein. Biochemistry, 1996, 35, 2830-2835;
50. Muñoz, A.; Petering, D. H.; Shaw III, C. F. Reactions of electrophilic reagents that target the thiolate groups of metallothionein clusters: Preferential reaction of the α-domain with 5,5′-dithiobis(2-nitrobenzoate) (DTNB) and aurothiomalate (AuSTm). Inorg. Chem., 1999, 38, 5655-5659.
51. 9) clusters. Inorg. Chem., 1992, 31, 1662-1667.
52. Muñoz, A.; Petering, D. H.; Shaw III, C. F. Structure-reactivity relationships among metallothionein three-metal domains: Role of non-cysteine amino acid residues in lobster metallothionein and human metallothionein-3. Inorg. Chem., 2000, 39, 6114-6123.
53. Mishina, Y.; Duguid, E. M.; He, C. Direct reversal of DNA alkylation damage. Chem. Rev., 2005, 106, 215-232.
54. 2C(O)NHPh: A mechanistic investigation of thiolate alkylation as probed by kinetics studies and by kinetic isotope effects. J. Am. Chem. Soc., 2005, 127, 14039-14050.
55. Greenwood, N. N.; Earnshaw, A. Chemistry of the Elements; Pergamon Press Ltd.: Oxford (UK), 1984.
56. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699;
57. Rosenberg, B.; Van Camp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds: A new class of potent antitumor agents. Nature, 1969, 222, 385-386.
58. Robillard, M. S.; Reedijk, J. Platinum-based anticancer drugs. In Encyclopedia of Inorganic Chemistry; 2 ed.; King, R. B. Ed.; John Wiley & Sons, Ltd.: Chichester (United Kingdom), 2005; pp 4488-4498.
59. Morris, M.; Eifel, P. J.; Lu, J.; Grigsby, P. W.; Levenback, C.; Stevens, R. E.; Rotman, M.; Gershenson, D. M.; Mutch, D. G. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk carvical cancer. N. Engl. J. Med., 1999, 340, 1137-1143;
60. Rose, P. G.; Bundy, B. N.; Watkins, E. B.; Thigpen, J. T.; Deppe, G.; Maiman, M. A.; Clarke-Pearson, D. L.; Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med., 1999, 340, 1144-1153;
61. Keys, H. M.; Bundy, B. N.; Stehman, F. B.; Mudersprach, L. I.; Chafe, W. E.; Suggs III., C. L.; Walker, J. L.; Gersell, D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med., 1999, 340, 1154-1161.
62. Bosl, G. J.; Motzer, R. J. Medical progress: Testicular gem-cell cancer. N. Engl. J. Med., 1997, 337, 242-253.
63. Ishida, S.; Lee, J.; Thiele, D. J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA, 2002, 99, 14298-14302.
64. Di Stasio, E. Anionic regulation of biological systems: The special role of chloride in the coagulation cascade. Biophys. Chem., 2004, 112, 245-252.
65. Reedijk, J. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 3611-3616.
66. Fuertes, M. A.; Alonso, C.; Pérez, J. M. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and cicumvention of drug resistance. Chem. Rev., 2003, 103, 645-662.
67. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug. Discov., 2005, 4, 307-320
68. Jung, Y.; Lippard, S. J. Direct cellular response to platinum-induced DNA damage. Chem. Rev., 2007, 107, 1387-1407.
69. Zorbas, H.; Keppler, B. K. Cisplatin damage: Are DNA repair proteins saviors or traitors to the cell? ChemBioChem, 2005, 6, 1157-1166.
70. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev., 1999, 99, 2467-2498.
71. Guo, Z.; Sadler, P. J. Metals in medicine. Angew. Chem. Int. Ed., 1999, 38, 1512-1531;
72. Kašparková, J.; Delalande, O.; Stros, M.; Elizondo-Riojas, M.-A.; Vojtíšková, M.; Kozelka, J.; Brabec, V. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein. Biochemistry, 2003, 42, 1234-1244
73. Brabec, V. DNA modifications by antitumor platinum and ruthenium compounds: Their recognition and repair. Progr. Nucl. Acid Res. Mol. Biol., 2002, 71, 1-68.
74. van den Berg, J. H.; Beijnen, J. H.; Balm, A. J. M.; Schellens, J. H. M. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat. Rev., 2006, 32, 390-397.
75. Zamble, D. B.; Lippard, S. J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci., 1995, 20, 435-439.
76. Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R. D.; Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 1996, 56, 4881-4886.
77. Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer, 1998, 34, 1522-1534.
78. Cvitkovic, E. Ongoing and unsaid on oxaliplatin: The hope. Br. J. Cancer, 1998, 77 (Suppl. 4), 8-11;
79. Bleiberg, H. Oxalipplatin (L-OHP): A new reality in colorectal cancer. Br. J. Cancer, 1998, 77 (Suppl. 4), 1-3.
80. Zhong, W.; Zhang, Q.; Yan, Y.; Yue, S.; Zhang, B.; Tang, W. Interaction of sodium chloroplatinate and iproplatin with metallothionein in vivo. J. Inorg. Biochem., 1997, 66, 159-164.
81. Reedijk, J. Improved understanding in platinum antitumor chemistry. Chem. Commun., 1996, 801-806.
82. 2(amine)(isopropylamine)] compounds: Cytotoxic activity and apoptosis induction in ras-transformed cells. J. Med. Chem., 1999, 42, 4264-4268.
83. Natile, G.; Coluccia, M. Current status of trans-platinum compounds in cancer therapy. Coord. Chem. Rev., 2001, 216-217, 383-410.
84. Brabec, V.; Kašparková, J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resistance Updates, 2005, 8, 131-146.
85. 3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol. Pharmacol., 2000, 58, 1525-1535.
86. McGowan, G.; Parsons, S.; Sadler, P. J. Contrasting chemistry of cis- and trans-platinum(II) diamine anticancer compounds: Hydrolysis studies of picoline complexes. Inorg. Chem., 2005, 44, 7459-7467.
87. Coluccia, M.; Nassi, A.; Loseto, F.; Boccarelli, A.; Mariggio, M. A.; Giordano, D.; Intini, F. P.; Caputo, P.; Natile, G. A trans-platinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem., 1993, 36, 510-512.
88. 2]. Mol. Pharmacol., 1997, 52, 354-361.
89. Raynaud, F. I.; Boxall, F. E.; Goddard, P. M.; Valenti, M.; Jones, M. E.; Murrer, B. A.; Abrams, M.; Kelland, L. R. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin. Cancer Res., 1997, 3, 2063-2074.
90. Kelland, L. R.; Sharp, S. Y.; O'Neill, C. F.; Raynaud, F. I.; Beale, P. J.; Judson, I. R. Mini-review: Discovery and development of platinum complexes designed to circumvent cisplatin resistance. J. Inorg. Biochem., 1999, 77, 111-115.
91. Kanzawa, F.; Akiyama, Y.; Saijo, N.; Nishio, K. In vitro effects of combinations of cis-amminedichloro(2-methylpyridine) platinum(II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer, 2003, 40, 325-332.
92. Holford, J.; Beale, P. J.; Boxall, F. E.; Sharp, S. Y.; Kelland, L. R. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur. J. Cancer, 2000, 36, 1984-1990.
93. Chen, Y.; Guo, Z.; Parsons, S.; Sadler, P. J. Stereospecific and kinetic control over the hydrolysis of a sterically hindered platinum picoline anticancer complex. Chem. Eur. J., 1998, 4, 672-676.
94. Sharma, R. P.; Edwards, I. R. cis-Platinum: Subcellular distribution and binding to cytosolic ligands. Biochem. Pharmacol., 1983, 32, 2665-2669.
95. Reedijk, J. Why does cisplatin reach guanine-N7 with competing S-domor ligands available in the cell? Chem. Rev., 1999, 99, 2499-2510.
96. Minami, T.; Tohono, Y.; Okazaki, Y.; Kubo, K.; Otaki, N.; Kimura, M. Quantitation of metallothionein isoforms in mouse liver on capillary zone electrophoresis. Anal. Chim. Acta, 1998, 372, 241-247.
97. Smith, D. J.; Jaggi, M.; Zhang, W.; Galich, A.; Du, C.; Sterrett, S. P.; Smith, L. M.; Balaji, K. C. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Urology, 2006, 67, 1341-1347.
98. Dutta, R.; Sens, D. A.; Somji, S.; Sens, M. A.; Garrett, S. H. Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate, 2002, 52, 89-97.
99. Kelley, S. L.; Basu, A.; Teicher, B. A.; Hacker, M. P.; Hamer, D. H.; Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science, 1988, 241, 1813-1815
100. Saga, Y.; Hashimoto, H.; Yachiku, S.; Iwata, T.; Tokumitsu, M. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int. J. Urol., 2004, 11, 407-415.
101. Endo, T.; Yoshikawa, M.; Ebara, M.; Kato, K.; Sunaga, M.; Fukuda, H.; Hayasaka, A.; Kondo, F.; Sugiura, N.; Saisho, H. Immunohistochemical metallothionein expression in hepatocellular carcinoma: Relation to tumor progression and chemoresistance to platinum agents. J. Gastroenterol., 2004, 39, 1196-1201.
102. Chu, G. Cellular response to cisplatin - The roles of DNA-binding proteins and DNA repair. J. Biol. Chem., 1994, 269, 787-790.
103. Woo, E. S.; Monks, A.; Watkins, S. C.; Wang, A. S.; Lazo, J. S. Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel. Cancer Chemother. Pharmacol., 1997, 41, 61-68.
104. Papouli, E.; Defais, M.; Larminat, F. Overexpression of metallothionein-II sensitizes rodent cells to apoptosis induced by DNA cross-linking agent through inhibition of NF-κB activation. J. Biol. Chem., 2002, 277, 4764-4769.
105. Ebadi, M.; Iversen, P. L. Metallothionein in carcinogenesis and cancer chemotherapy. Gen. Pharmacol., 1994, 25, 1297-1310.
106. Dziegiel, P. Expression of metallothioneins in tumor cells. Pol. J. Pathol., 2004, 55, 3-12.
107. Wei, H.; Desouki, M. M.; Lin, S. J.; Xiao, D.; Franklin, R. B.; Feng, P. Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissue. Mol. Cancer, 2008, 7.
108. Garrett, S. H.; Sens, M. A.; Shukla, D.; Flores, L.; Somji, S.; Todd, J. H.; Sens, D. A. Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT-1X in advanced prostate cancer. Prostate, 2000, 43, 125-135.
109. Ohshio, G.; Imamura, T.; Okada, N.; Wang, Z.-h.; Yamaki, K.; Kyogoku, T.; Suwa, H.; Yamabe, H.; Imamura, M. Immunohistochemical study of metallothionein in pancreatic carcinomas. J. Cancer Res. Clin. Oncol., 1996, 122, 351-355.
110. Eid, H.; Géczi, L.; Bodrogi, I.; Institoris, E.; Bak, M. Do metallothioneins affect the response to treatment in testis cancers? J. Cancer Res. Clin. Oncol., 1998, 124, 31-36.
111. Adam, V.; Baloun, J.; Fabrik, I.; Trukova, L.; Kizek, R. An electrochemical detection of metallothioneins at the zeptomole level in nanoliter volumes. Sensors, 2008, 8, 2293-2305.
112. Huang, Q.; Dunn II, R. T.; Jayadev, S.; DiSorbo, O.; Pack, F. D.; Farr, S. B.; Stoll, R. E.; Blanchard, K. T. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci., 2001, 63, 196-207.
113. Zhu, K.; Fukasawa, I.; Fujinoki, M.; Furuno, M.; Inaba, F.; Yamazaki, T.; Kamemori, T.; Kousaka, N.; Ota, Y.; Hayashi, M.; Maehama, T.; Inaba, N. Profiling of proteins associated with cisplatin resistance in ovarian cancer cells. Int. J. Gynecol. Cancer, 2005, 15, 747-754.
114. Chekhun, V. F.; Lukyanova, N. Y.; Urchenko, O. V.; Kulik, G. I. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp. Oncol., 2005, 27, 191-195.
115. Wang, Y.; Chiu, J.-F. Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs. Metal-Based Drugs, 2008.
116. Ranford, J. D.; Rhodes, M. D.; Sadler, P. J. Metallodrugs. The role of thiolate proteins and metal-thiolate complexes. In Metallothioneins: Synthesis, Structure and Properties of Metallothioneins, Phytochelatines, and Metal-Thiolate; (Stillman, M. J., Shaw III, C. F., Suzuki, K. T., Eds.); VCH Publishers, Inc.: New York (United States), 1992; pp 408-435;
117. Zelazowski, A. J.; Garvey, J. S.; Hoeschele, J. D. In vivo and in vitro binding of platinum to metallothionein. Arch. Biochem. Biophys., 1984, 229, 246-252.
118. Sack, R.; Willi, A.; Hunziker, P. E. Determination of total glutathione in cell lysates by high performance liquid chromatography with o-phthalaldehyde precolumn derivatization in the presence of tris(2-carboxyethyl)-phosphine. J. Liq. Chrom. Rel. Technol., 2000, 23, 2947-2962.
119. Brinkmann, M. J. Volumetrie des rechten Leberlappens vor und während der Leberspende - Vergleich verschiedener Verfahren, Thesis, Faculty of Medicine, University of Berlin, Berlin (Germany), 2005.
120. Braun, O.; Knipp, M.; Chesnov, S.; Vašák, M. Specific reactions of S-nitrosothiols with cysteine hydrolases: A comparative study between dimethylargininase-1 and CTP synthetase. Prot. Sci., 2007, 16, 1522-1534.
121. Esteban-Fernández, D.; Cañas, B.; Pizarro, I.; Palacios, M. A.; Gómez-Gómez, M. M. SEC-ICP-MS and ESI-MS as tools to study the interaction between cisplatin and cytosolic biomolecules. J. Anal. Atomic Spectrom., 2007, 22, 1113-1121.
122. Hagrman, D.; Goodisman, J.; Dabrowiak, J. C.; Souid, A.-K. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab. Disposition, 2003, 31, 916-923.
123. Zhang, B.; Tang, W.; Gao, S.; Zhou, Y. Platinum binding to metallothionein. Analysis of circular dichroism spectra of complexes formed between metallothionein and platinum from cis- and trans-diamminedichloroplatinum. J. Inorg. Biochem., 1995, 58, 9-19.
124. Pattanaik, A.; Bachowski, G.; Laib, J.; Lemkuil, D.; Shaw III., C. F.; Petering, D. H.; Hitchcock, A.; Saryan, L. Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein. J. Biol. Chem., 1992, 267, 16121-16128.
125. Bongers, J.; Bell, J. U.; Richardson, D. E. Platinum(II)-thiolate cluster formation in heptaplatinum metallothionein. Inorg. Chem., 1991, 30, 515-519.
126. Zhang, B.; Huang, H.; Tang, W. Interaction of cis- and trans-diamminedichloroplatinum with metallothionein in vivo. J. Inorg. Biochem., 1995, 58, 1-8.
127. Bongers, J.; Bell, J. U.; Richardson, D. E. Platinum(II) binding to metallothionein. J. Inorg. Biochem., 1988, 34, 55-62.
128. 7-metallothionein with cis-dichlorodiammine platinum(II). J. Biol. Chem., 1994, 269, 24792-24797.
129. Zhang, B.; Tang, W. Kinetics of the reaction of platinum(II) complexes with metallothionein. J. Inorg. Biochem., 1994, 56, 143-153.
130. Zhang, B. L.; Sun, W. Y.; Tang, W. X. Determination of the association constant of platinum(II) to metallothionein. J. Inorg. Chem., 1997, 65, 295-298.
131. Kägi, J. H. R.; Vallee, B. L. Metallothionein: A cadmium and zinc-containing protein from equine renal cortex. II. Physicochemical properties. J. Biol. Chem., 1961, 236, 2435-2442
132. 7]-metallothionein-1 by homonuclear and heteronuclear NMR spectroscopy. Protein Sci., 1999, 8, 2630-2638.
133. Otvos, J. D.; Liu, X.; Li, H.; Shen, G.; Basti, M. Dynamic aspects of metallothionein structure. In Metallothionein III: Biological Roles and Medical Implications; (Suzuki, K. T., Imura, N., Kimura, M., Eds.); Birkhäuser Verlag: Basel (Switzerland), 1993; pp 57-74.
134. 2. Can. J. Chem., 1982, 60, 2075-2081.
135. Gibson, D.; Lippard, S. J. Preparation and structural characterization of a novel hexanuclear complex of platinum(II) with 2-aminoethanethiolate. Inorg. Chem., 1986, 25, 219-222.
136. Knipp, M.; Charnock, J. M.; Garner, C. D.; Vašák, M. Structural and functional characterization of the Zn(II)-site in dimethylargininase-1 (DDAH-1) from bovine brain - Zn(II) release activates DDAH-1. J. Biol. Chem., 2001, 276, 40449-40456.
137. 18-MT formed from rabbit liver metallothionein 2. J. Am. Chem. Soc., 1994, 116, 11004-11013.
138. Melnik, M.; Holloway, C. E. Stereochemistry of platinum coordination compounds. Coord. Chem. Rev., 2006, 250, 2261-2270.
139. Dance, I. G. The structural chemistry of metal thiolate complexes. Polyhedron, 1986, 5, 1037-1104.
140. Albrecht, C.; Schwieger, S.; Bruhn, C.; Wagner, C.; Kluge, R.; Schmidt, H.; Steinborn, D. Alkylthio bridged 44 cve triangular platinum clusters: Synthesis, oxidation, degradation, ligand substitution, and quantum chemical calculations. J. Am. Chem. Soc., 2007, 129, 4551-4566.
141. McPartlin, E. M.; Stephenson, N. C. The structure of 2,2′dimercaptodiethylsulphidepalladium(II): A trimeric molecule containing bridging sulphur atoms. Acta Cryst., 1969, B25, 1659-1666.
142. Lau, J. K.-C.; Deubel, D. V. Loss of ammine from platinum(II) complexes: Implications for cisplatin inactivation, storage, and resistance. Chem. Eur. J., 2005, 11, 2849-2855.
143. Casini, A.; Guerri, A.; Gabbiani, C.; Messori, L. Biophysical characterization of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. J. Inorg. Biochem., 2008, 102, 995-1006.
144. Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler, B. K.; Dyson, P. J. Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. J. Anal. At. Spectrom., 2007, 22, 960-967.
145. Djuran, M. I.; Lempers, E. L. M.; Reedijk, J. Reactivity of chloroand aqua(diethylenetriamine)platinum(II) ions with glutathione, Smethylglutathione, and guanosine 5′-monophosphate in relation to the antitumor activity and toxicity of platinum complexes. Inorg. Chem., 1991, 30, 2648-2652.
146. Stillman, M. J.; Zelazowski, A. J.; Szymanska, J.; Gasyna, Z. Luminescent metallothioneins: Emission properties of copper, silver, gold and platinum complexes of MT. Inorg. Chim. Acta, 1989, 161, 275-279.
147. Holleman, A. F.; Wiberg, E.; Wiberg, N. Inorganic Chemistry; 101 ed.; Walter de Gruyter: Berlin, New York, 2001.
148. Kašparková, J.; Marini, V.; Najajreh, Y.; Gibson, D.; Brabec, V. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry, 2003, 42, 6321-6332.
149. Trynda-Lemiesz, L.; Kozłowski, H.; Keppler, B. K. Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin. J. Inorg. Chem., 1999, 77, 141-146.
150. Peleg-Shulman, T.; Gibson, D. Cisplatin-protein adducts are efficiently removed by glutathione but not by 5′-guanosine monophosphate. J. Am. Chem. Soc., 2001, 123, 3171-3172.
151. Peleg-Shulman, T.; Gibson, D. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles. J. Inorg. Biochem., 2002, 91, 306-311.
152. 2] to proteins. J. Biol. Inorg. Chem., 2003, 8, 167-175.
153. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini, F. P.; Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Insights into the molecular mechanisms of protein platination from a case study: The reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. Biochemistry, 2007, 46, 12220-12230.
154. Allardyce, C. S.; Dyson, P. J.; Coffey, J.; Johnson, N. Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: The interaction of cisplatin with transferrin. Rapid Comm. Mass Spectrometry, 2002, 16, 933-935.
155. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Moneti, G.; Pieraccini, G. Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome c. ChemMedChem, 2006, 1, 413-417.
156. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106, 2224-2248.
157. Palmiter, R. D. Regulation of metallothionein genes by heavy metals appears to be mediated by a sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc. Natl. Acad. Sci. USA, 1994, 91, 1219-1223.
158. Davis, S. R.; Cousins, R. J. Metallothionein expression in animals: A physiological perspective on function. J. Nutr., 2000, 130, 1085-1088.
159. Kindermann, B.; Döring, F.; Budczies, J.; Daniel, H. Zinc-sensitive genes as potential new target genes of the metal transcription factor-1 (MTF-1). Biochem. Cell Biol., 2005, 83, 221-229
160. Schimura, M.; Saito, A.; Matsuyama, S.; Sakuma, T.; Terui, Y.; Ueno, K.; Yumoto, H.; Yamauchi, K.; Yamamura, K.; Mimura, H.; Sano, Y.; Yabashi, M.; Tamasaku, K.; Nishio, K.; Nishino, Y.; Endo, K.; Hatake, K.; Mori, Y.; Ishizaka, Y.; Ishikawa, T. Element array by scanning X-ray fluorescence microscopy after cisdiamminedichloro- platinum(II) treatment. Cancer Res., 2005, 65, 4998-5002.
161. 7metallothionein-3 and the synaptic vesicle cycle: Interaction of metallothionein-3 with the small GTPase Rab3A. Biochemistry, 2005, 44, 3159-3165;
162. El Ghazi, I.; Martin, B. L.; Armitage, I. M. Metallothionein-3 is a component of a multiprotein complex in the mouse brain. Exp. Biol. Med., 2006, 231, 1500-1506;
163. Meloni, G.; Knipp, M.; Roschitzki, B.; Vašák, M. Metallothionein-3 and the synaptic vesicle cycle: Interaction of
164. Vrána, O.; Brabec, V. L-Methionein inhibits reaction of DNA with anticancer cis-diamminedichloroplatinum(II). Biochemistry, 2002, 36, 10994-10999.
165. Ismail, I. M.; Sadler, P. J. In Platinum, gold, and other metal chemotherapeutic agents: Chemistry and Biochemistry; (Lippard, S. J., Eds.); American Chemical Society, 1983; pp 171.
166. Cherian, M. G. The significance of the nuclear and cytoplasmic localization of metallothionein in human liver and tumor cells. Environ. Health. Perspect., 1994, 102 (Suppl. 13), 131-135.
167. Sterling, K. M.; Mandal, P. K.; Roggenbeck, B. A.; Ahearn, S. E.; Gerencser, G. A.; Ahearn, G. A. Heavy metal detoxification in crustacean epithelial lysosomes; Role of anions in the compartimentaliyation process. J. Exp. Biol., 2007, 210, 3483-3493.
168. Safaei, R.; Larson, B. J.; Cheng, T. C.; Gibson, M. A.; Otani, S.; Naerdemann, W.; Howell, S. B. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther., 2005, 4, 1595-1604.
169. Safaei, R.; Katano, K.; Larson, B. J.; Samimi, G.; Holzer, A. K.; Naerdemann, W.; Tomioka, M.; Goodman, M.; Howell, S. B. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin. Cancer Res., 2005, 11, 756-767.
170. McGrath, M. E. The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct., 1999, 28, 181-204.
171. Choudhuri, S.; McKim, J. M., Jr.; Klaassen, C. D. Role of hepatic lysosomes in the degradation of metallothionein. Toxicol. Appl. Pharmacol., 1992, 115, 64-71.
172. Min, K.-S.; Nakatsubo, T.; Fujita, Y.; Onosaka, S.; Tanaka, K. Degradation of cadmium metallothionein in vitro by lysosomal proteases. Toxicol. Appl. Pharmacol., 1992, 113, 299-305.
173. Winge, D. R. Limited proteolysis of metallothioneins. Methods Enzymol., 1991, 205, 438-447.
174. Jedeszko, C.; Sloane, B. F. Cysteine cathepsins in human cancer. Biol. Chem., 2004, 385, 1017-1027.
175. Centerwall, C. R.; Goodisman, J.; Kerwood, D. J.; Dabrowiak, J. C. Cisplatin carbonato complexes. Implications for uptake, antitumor properties, and toxicity. J. Am. Chem. Soc., 2005, 127, 12768-12769.